التفاصيل البيبلوغرافية
| العنوان: |
Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. |
| المؤلفون: |
Martinelli, E., De Palma, R., Orditura, M., De Vita, F., Ciardiello, F. |
| المصدر: |
Clinical & Experimental Immunology; Oct2009, Vol. 158 Issue 1, p1-9, 9p, 2 Diagrams, 3 Charts |
| مصطلحات موضوعية: |
CANCER treatment, IMMUNOGLOBULINS, EPIDERMAL growth factor, MONOCLONAL antibodies |
| مستخلص: |
The epidermal growth factor receptor (EGFR) is a transmembrane tyrosine kinase receptor involved in the proliferation and survival of cancer cells. EGFR is the first molecular target against which monoclonal antibodies (mAb) have been developed for cancer therapy. Here we review the mechanisms underlying the effects of EGFR-specific mAb in cancer therapy. The efficacy of EGFR-specific mAb in cancer occurs thanks to inhibition of EGFR-generated signalling; furthermore, the effects of antibodies on the immune system seem to play an important role in determining the overall anti-tumour response. In this review, attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical & Experimental Immunology is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder